Volume | 712,941 |
|
|||||
News | - | ||||||
Day High | 1.80 | Low High |
|||||
Day Low | 1.74 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Xeris Biopharma Holdings Inc | XERS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.78 | 1.74 | 1.80 | 1.76 | 1.785 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,379 | 712,941 | $ 1.76 | $ 1,254,332 | - | 1.46 - 3.26 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:07:57 | formt | 8,500 | $ 1.76 | USD |
Xeris Biopharma Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
248.6M | 140.45M | - | 163.91M | -62.26M | -0.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Xeris Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XERS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.80 | 1.90 | 1.69 | 1.77 | 1,456,245 | -0.04 | -2.22% |
1 Month | 2.08 | 2.2799 | 1.69 | 1.96 | 1,511,469 | -0.32 | -15.38% |
3 Months | 2.52 | 3.26 | 1.69 | 2.50 | 1,953,446 | -0.76 | -30.16% |
6 Months | 1.72 | 3.26 | 1.46 | 2.35 | 1,918,425 | 0.04 | 2.33% |
1 Year | 2.33 | 3.26 | 1.46 | 2.37 | 1,492,067 | -0.57 | -24.46% |
3 Years | 3.97 | 4.98 | 0.9701 | 2.47 | 1,837,699 | -2.21 | -55.67% |
5 Years | 9.68 | 12.98 | 0.9701 | 3.22 | 1,644,631 | -7.92 | -81.82% |
Xeris Biopharma Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. |